AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks.

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 countries with more than 80,000 employees. Formed in 1999 through the merger of Astra AB and Zeneca Group, the company is a leader in oncology, rare diseases, and biopharmaceuticals, with R&D hubs in Cambridge (UK), Gothenburg (Sweden), and Gaithersburg (US).

A major recent milestone for the company is the U.S. FDA approval of Datroway (datopotamab deruxtecan) for patients with EGFR-mutated, previously treated non-small cell lung cancer (NSCLC). Datroway is the first TROP2-directed antibody-drug conjugate approved for this indication and offers improved progression-free and overall survival compared to chemotherapy, based on results from the Phase III TROPION-Lung01 trial. The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)’s focus on collaborative innovation.

This approval strengthens the company’s extensive oncology portfolio, which includes Tagrisso, Imfinzi, and Enhertu, and supports its leadership in targeted cancer therapies.

Beyond lung cancer, AZN is advancing treatments across other cancers. The SERENA-6 trial showed positive Phase III results for camizestrant, an oral SERD for HR-positive breast cancer, while the MATTERHORN trial reported promising data for Imfinzi in early-stage gastric and gastroesophageal junction cancers.

AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough

A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

AstraZeneca PLC (NASDAQ:AZN) continues to drive global oncology research, regularly presenting plenary data at leading medical conferences like ASCO, reflecting its position at the forefront of cancer innovation.

While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.